Physician profile
Wilson Lopez
NPI 1568492528
$5,158.88
in general payments reported to CMS, 2019-2025
27 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $922 · 2020: $785 · 2021: $694 · 2022: $457 · 2023: $671 · 2024: $765 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $836.47 | 2019-2024 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $627.33 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $584.27 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $443.99 | 2020-2025 | Airsupra, Bevespi Aerosphere |
| Amgen INC. | $352.03 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $302.28 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $268.23 | 2019-2021 | |
| Exact Sciences Corporation | $256.51 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $194.29 | 2023-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $179.34 | 2019-2021 | |
| Shield Therapeutics INC | $166.04 | 2025 | |
| Pfizer INC. | $131.81 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $114.26 | 2025 | Zoryve |
| Ibsa Pharma INC. | $99.63 | 2020-2023 | Tirosint, Licart |
| Amneal Pharmaceuticals LLC | $86.56 | 2019-2023 | Unithroid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.52 | 2019-2025 | |
| Intuitive Surgical, INC. | $72.93 | 2019 | |
| Abbott Laboratories | $69.52 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $58.84 | 2024 | Voquezna |
| Phadia US INC. | $51.00 | 2021-2025 | Immunocap |
| Hologic Sales and Service, LLC | $36.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.79 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $34.80 | 2020-2021 | |
| Inspire Medical Systems, INC. | $22.94 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $20.09 | 2023 | Quviviq |
| Dermira, INC. | $17.36 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.